JP2009522339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009522339A5 JP2009522339A5 JP2008549020A JP2008549020A JP2009522339A5 JP 2009522339 A5 JP2009522339 A5 JP 2009522339A5 JP 2008549020 A JP2008549020 A JP 2008549020A JP 2008549020 A JP2008549020 A JP 2008549020A JP 2009522339 A5 JP2009522339 A5 JP 2009522339A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- blocks
- maturation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000003112 inhibitor Substances 0.000 claims 19
- 102000000589 Interleukin-1 Human genes 0.000 claims 15
- 108010002352 Interleukin-1 Proteins 0.000 claims 15
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 10
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 10
- 108010034143 Inflammasomes Proteins 0.000 claims 9
- 230000035800 maturation Effects 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 5
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 4
- KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 4
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 2
- 229960004238 anakinra Drugs 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 229960002708 antigout preparations Drugs 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims 2
- -1 cortibazole Chemical compound 0.000 claims 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229950007866 tanespimycin Drugs 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 208000009766 Blau syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 208000018619 Parkinson disease 23 Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 108010092464 Urate Oxidase Proteins 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 201000003377 familial cold autoinflammatory syndrome 1 Diseases 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960002871 tenoxicam Drugs 0.000 claims 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2006/050060 WO2007077042A1 (en) | 2006-01-06 | 2006-01-06 | New method for the treatment of gout or pseudogout |
| US11/539,851 US20070161559A1 (en) | 2006-01-06 | 2006-10-09 | Method for the treatment of gout or pseudogout |
| PCT/EP2007/050143 WO2007077261A1 (en) | 2006-01-06 | 2007-01-08 | New method for the treatment of gout or pseudogout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009522339A JP2009522339A (ja) | 2009-06-11 |
| JP2009522339A5 true JP2009522339A5 (enExample) | 2010-02-25 |
Family
ID=35998432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008549020A Pending JP2009522339A (ja) | 2006-01-06 | 2007-01-08 | 痛風または偽痛風の新規な治療法 |
Country Status (3)
| Country | Link |
|---|---|
| US (4) | US20070161559A1 (enExample) |
| JP (1) | JP2009522339A (enExample) |
| WO (2) | WO2007077042A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7632490B2 (en) | 2006-10-20 | 2009-12-15 | Regeneron Pharmaceuticals, Inc. | Use of IL-1 antagonists to treat gout |
| MX2009004051A (es) * | 2006-10-20 | 2009-05-11 | Regeneron Pharma | Uso de antagonistas de il-1 para tratar gota y pseudo gota. |
| BRPI0819847B1 (pt) | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
| DK2391650T3 (en) * | 2007-12-20 | 2015-01-12 | Xoma Us Llc | Methods of treating gout |
| EP2300000A1 (en) * | 2008-07-03 | 2011-03-30 | University of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| US8242154B2 (en) | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| EP2165705A1 (en) * | 2008-09-18 | 2010-03-24 | Centre National de la Recherche Scientifique (CNRS) | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
| AU2011252883B2 (en) | 2010-05-14 | 2015-09-10 | Abbvie Inc. | IL-1 binding proteins |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| WO2012078101A1 (en) * | 2010-12-07 | 2012-06-14 | Swedish Orphan Biovitrum Ab (Publ) | Method for the treatment of il-1 mediated diseases |
| WO2012123299A1 (en) * | 2011-03-11 | 2012-09-20 | Roche Diagnostics Gmbh | Asc as marker for chronic obstructive pulmonary disease (copd) |
| ES2907620T3 (es) | 2011-07-18 | 2022-04-25 | Univ Kentucky Res Found | Protección de células de la degeneración inducida por ARN Alu e inhibidores para proteger células |
| US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
| NZ702169A (en) | 2012-05-25 | 2016-10-28 | Berg Llc | The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome |
| WO2015188198A2 (en) | 2014-06-06 | 2015-12-10 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
| US9938528B2 (en) * | 2014-12-11 | 2018-04-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections |
| EP3297694A1 (en) | 2015-05-21 | 2018-03-28 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
| CN108351351B (zh) * | 2015-11-09 | 2021-10-29 | 生物辐射实验室股份有限公司 | 使用亲和素和生物素的试验 |
| US20200315540A1 (en) * | 2016-12-14 | 2020-10-08 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| US12566174B2 (en) | 2017-05-11 | 2026-03-03 | The Research Foundation For The State University Of New York | Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid |
| GB201815045D0 (en) | 2018-09-14 | 2018-10-31 | Univ Ulster | Bispecific antibody targeting IL-1R1 and NLPR3 |
| CN111067911A (zh) * | 2018-10-18 | 2020-04-28 | 刘琦 | 白头翁皂苷b4抗急性痛风性关节炎的医药用途 |
| WO2024102997A1 (en) * | 2022-11-11 | 2024-05-16 | Peterson Jeff R | Gout flare prevention methods using il-1β inhibitors |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6511665B1 (en) * | 1987-11-25 | 2003-01-28 | Immunex Corporation | Antibodies to interleukin-1 receptors |
| US5872095A (en) * | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
| JPH1072421A (ja) * | 1996-07-02 | 1998-03-17 | Nisshin Flour Milling Co Ltd | イミド誘導体 |
| EP0818439B1 (en) * | 1996-07-02 | 1999-10-13 | Nisshin Flour Milling Co., Ltd. | Imide derivatives |
| US6770647B2 (en) * | 2001-08-17 | 2004-08-03 | Bristol-Myers Squibb Pharma Company | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| EP1481010A2 (en) * | 2002-02-28 | 2004-12-01 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
-
2006
- 2006-01-06 WO PCT/EP2006/050060 patent/WO2007077042A1/en not_active Ceased
- 2006-10-09 US US11/539,851 patent/US20070161559A1/en not_active Abandoned
-
2007
- 2007-01-08 US US12/159,842 patent/US20090022704A1/en not_active Abandoned
- 2007-01-08 WO PCT/EP2007/050143 patent/WO2007077261A1/en not_active Ceased
- 2007-01-08 JP JP2008549020A patent/JP2009522339A/ja active Pending
-
2011
- 2011-07-01 US US13/175,266 patent/US20110262449A1/en not_active Abandoned
-
2013
- 2013-07-16 US US13/943,638 patent/US20130302344A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Becker | Pain management: Part 1: Managing acute and postoperative dental pain | |
| Doan et al. | Rheumatoid arthritis: an overview of new and emerging therapies | |
| WO2007002543A8 (en) | Antibody formulations having optimized aggregation and fragmentation profiles | |
| US9149499B1 (en) | Cannabis based therapeutic and method of use | |
| Schlesinger | Anti-interleukin-1 therapy in the management of gout | |
| IL193444A (en) | Isolated reactive monoclonal antibody that binds both IL-17a and IL-17f, an isolated serum containing it, a diagnostic kit containing it, a pharmaceutical product containing it, and its use as a drug to treat or prevent inflammation or inflammatory disease. | |
| JP2023506147A5 (enExample) | ||
| JP2017079785A5 (enExample) | ||
| JP2005533005A5 (enExample) | ||
| JP2007530577A5 (enExample) | ||
| WO2007096151A3 (en) | Inhibitors of p38-kinase for treatment of pulmonary hypertension | |
| JP2013512280A5 (enExample) | ||
| JP2013521303A5 (enExample) | ||
| CN105050624A (zh) | 利用阿普斯特来治疗银屑病关节炎的方法 | |
| JP2008509137A5 (enExample) | ||
| JP2013544244A5 (enExample) | ||
| KR20100099178A (ko) | Ｐ2ｘ7 조절제로서의 5-옥소-3-피롤리딘카르복스아미드 유도체 | |
| JP2010511631A5 (enExample) | ||
| JP2008543936A5 (enExample) | ||
| JP2005533104A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| Betrains et al. | Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review | |
| JP2008505107A5 (enExample) | ||
| TW200902027A (en) | Compositions and methods for treating medical conditions | |
| JP2021506778A5 (enExample) |